Геморагічний синдром у пацієнтів з гострою мієлоїдною лейкемією та вплив порушень системи згортання крові на перебіг захворювання

Q3 Medicine
З.В. Ступакова, Геморагічний синдром, перебіг захворювання
{"title":"Геморагічний синдром у пацієнтів з гострою мієлоїдною лейкемією та вплив порушень системи згортання крові на перебіг захворювання","authors":"З.В. Ступакова, Геморагічний синдром, перебіг захворювання","doi":"10.32471/clinicaloncology.2663-466x.43-3.28569","DOIUrl":null,"url":null,"abstract":". Bleeding events are considered among the most common and dangerous complications in patients with newly diagnosed acute myeloid leukemia (AML) and severely impacts survival rates at the time of the diagnosis and in different periods of treatment. Bleeding in a patient with AML is usually associated with low platelet counts, coagulation disorders due to reduced platelet functions or abnormalities in the external or internal coagulation pathways. Prophylactic platelet transfusions considered as the main method of prevention of bleeding in patients with thrombocytopenia at different stages of diagnosis and treatment of AML. Von Willebrand factor is a large glycoprotein that circulates in plasma and is released from alpha granules of platelets and endothelial cells in response to various stimuli. It provides two main functions: it mediates the adhesion of platelets to the sites of vascular wall damage and also as it binds and stabilizes the procoagulant protein — coagulation factor VIII. A comprehensive analysis of the functional activity of vWF is defined for many lymphoproliferative and myeloproliferative diseases and is taken into account when prescribing treatment in these patients. Despite the available scales for assessing the risk of bleeding — IMPROVE, ATRIA, HAS-BLED, HEMORR2HAGES, etc., almost all of them are developed for elderly patients or those taking direct oral anticoagulants or warfarin. This paper presents a review of literature data on the frequency and main mechanisms of hemorrhagic syndrome in patients with AML, evaluation of the effectiveness of platelet transfusions in hematological patients according to the latest data and possible additional mechanisms of bleeding in patients with AML.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/clinicaloncology.2663-466x.43-3.28569","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

. Bleeding events are considered among the most common and dangerous complications in patients with newly diagnosed acute myeloid leukemia (AML) and severely impacts survival rates at the time of the diagnosis and in different periods of treatment. Bleeding in a patient with AML is usually associated with low platelet counts, coagulation disorders due to reduced platelet functions or abnormalities in the external or internal coagulation pathways. Prophylactic platelet transfusions considered as the main method of prevention of bleeding in patients with thrombocytopenia at different stages of diagnosis and treatment of AML. Von Willebrand factor is a large glycoprotein that circulates in plasma and is released from alpha granules of platelets and endothelial cells in response to various stimuli. It provides two main functions: it mediates the adhesion of platelets to the sites of vascular wall damage and also as it binds and stabilizes the procoagulant protein — coagulation factor VIII. A comprehensive analysis of the functional activity of vWF is defined for many lymphoproliferative and myeloproliferative diseases and is taken into account when prescribing treatment in these patients. Despite the available scales for assessing the risk of bleeding — IMPROVE, ATRIA, HAS-BLED, HEMORR2HAGES, etc., almost all of them are developed for elderly patients or those taking direct oral anticoagulants or warfarin. This paper presents a review of literature data on the frequency and main mechanisms of hemorrhagic syndrome in patients with AML, evaluation of the effectiveness of platelet transfusions in hematological patients according to the latest data and possible additional mechanisms of bleeding in patients with AML.
严重髓系白血病患者的出血综合征及凝血障碍对疾病预防的影响
出血事件被认为是新诊断的急性髓细胞白血病(AML)患者最常见和最危险的并发症之一,严重影响诊断时和不同治疗期的生存率。AML患者的出血通常与血小板计数低、血小板功能降低引起的凝血障碍或外部或内部凝血途径异常有关。在AML的不同诊断和治疗阶段,预防性血小板输注被认为是预防血小板减少症患者出血的主要方法。Von Willebrand因子是一种在血浆中循环的大糖蛋白,在各种刺激下从血小板和内皮细胞的α颗粒中释放。它提供两种主要功能:介导血小板与血管壁损伤部位的粘附,以及结合和稳定促凝蛋白——凝血因子VIII。vWF功能活性的综合分析被定义为许多淋巴增生性和骨髓增生性疾病,并在为这些患者开具治疗处方时予以考虑。尽管有评估出血风险的可用量表——PROVEE、ATRIA、HAS-BLED、HEMORR2HAGES等,但几乎所有这些量表都是为老年患者或直接口服抗凝血剂或华法林的患者开发的。本文综述了关于AML患者出血综合征的频率和主要机制的文献数据,根据最新数据评估血液病患者输注血小板的有效性,以及AML患者出血的可能的其他机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Experimental oncology
Experimental oncology Medicine-Oncology
CiteScore
1.40
自引率
0.00%
发文量
49
期刊介绍: The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信